Optimal Antipsychotic Dose and Dosing Interval in the Treatment of Schizophrenia

Research output: Contribution to journalReview article

Abstract

While antipsychotic treatment is essential for acute and maintenance phases of schizophrenia, antipsychotics can induce various undesirable side effects. Thus, antipsychotic dose and dosing interval should be optimized for each patient. Some of the side effects of antipsychotics, including cognitive impairment, are related to antipsychotic dose. To date, there have been only a few studies examining the effect of atypical antipsychotic dose reduction on clinical outcomes, and there has been no study employing neurocognitive assessments. Based on this background, we conducted a randomized controlled trial and found that atypical antipsychotic reduction significantly improved cognitive function without an increased risk of relapse. In addition, we analyzed the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) data, revealing that there were no significant differences in clinical outcomes between once- vs. twice-daily perphenazine dosing regimens; however, the mean dose of perphenazine was significantly lower with once-daily dosing than that with twice-daily dosing. These findings suggest the possibility of effective antipsychotic treatment with lower doses and longer dosing intervals.

Original languageEnglish
Pages (from-to)562-567
Number of pages6
JournalSeishin shinkeigaku zasshi = Psychiatria et neurologia Japonica
Volume117
Issue number7
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Perphenazine
Therapeutics
Cognition
Randomized Controlled Trials
Maintenance
Clinical Trials
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{9087cb8f44214fe79709ca264753664f,
title = "Optimal Antipsychotic Dose and Dosing Interval in the Treatment of Schizophrenia",
abstract = "While antipsychotic treatment is essential for acute and maintenance phases of schizophrenia, antipsychotics can induce various undesirable side effects. Thus, antipsychotic dose and dosing interval should be optimized for each patient. Some of the side effects of antipsychotics, including cognitive impairment, are related to antipsychotic dose. To date, there have been only a few studies examining the effect of atypical antipsychotic dose reduction on clinical outcomes, and there has been no study employing neurocognitive assessments. Based on this background, we conducted a randomized controlled trial and found that atypical antipsychotic reduction significantly improved cognitive function without an increased risk of relapse. In addition, we analyzed the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) data, revealing that there were no significant differences in clinical outcomes between once- vs. twice-daily perphenazine dosing regimens; however, the mean dose of perphenazine was significantly lower with once-daily dosing than that with twice-daily dosing. These findings suggest the possibility of effective antipsychotic treatment with lower doses and longer dosing intervals.",
author = "Hiroyoshi Takeuchi",
year = "2015",
language = "English",
volume = "117",
pages = "562--567",
journal = "Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica",
issn = "0033-2658",
publisher = "Japanese Society of Psychiatry and Neurology",
number = "7",

}

TY - JOUR

T1 - Optimal Antipsychotic Dose and Dosing Interval in the Treatment of Schizophrenia

AU - Takeuchi, Hiroyoshi

PY - 2015

Y1 - 2015

N2 - While antipsychotic treatment is essential for acute and maintenance phases of schizophrenia, antipsychotics can induce various undesirable side effects. Thus, antipsychotic dose and dosing interval should be optimized for each patient. Some of the side effects of antipsychotics, including cognitive impairment, are related to antipsychotic dose. To date, there have been only a few studies examining the effect of atypical antipsychotic dose reduction on clinical outcomes, and there has been no study employing neurocognitive assessments. Based on this background, we conducted a randomized controlled trial and found that atypical antipsychotic reduction significantly improved cognitive function without an increased risk of relapse. In addition, we analyzed the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) data, revealing that there were no significant differences in clinical outcomes between once- vs. twice-daily perphenazine dosing regimens; however, the mean dose of perphenazine was significantly lower with once-daily dosing than that with twice-daily dosing. These findings suggest the possibility of effective antipsychotic treatment with lower doses and longer dosing intervals.

AB - While antipsychotic treatment is essential for acute and maintenance phases of schizophrenia, antipsychotics can induce various undesirable side effects. Thus, antipsychotic dose and dosing interval should be optimized for each patient. Some of the side effects of antipsychotics, including cognitive impairment, are related to antipsychotic dose. To date, there have been only a few studies examining the effect of atypical antipsychotic dose reduction on clinical outcomes, and there has been no study employing neurocognitive assessments. Based on this background, we conducted a randomized controlled trial and found that atypical antipsychotic reduction significantly improved cognitive function without an increased risk of relapse. In addition, we analyzed the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) data, revealing that there were no significant differences in clinical outcomes between once- vs. twice-daily perphenazine dosing regimens; however, the mean dose of perphenazine was significantly lower with once-daily dosing than that with twice-daily dosing. These findings suggest the possibility of effective antipsychotic treatment with lower doses and longer dosing intervals.

UR - http://www.scopus.com/inward/record.url?scp=84952715269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952715269&partnerID=8YFLogxK

M3 - Review article

C2 - 26552322

AN - SCOPUS:84952715269

VL - 117

SP - 562

EP - 567

JO - Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica

JF - Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica

SN - 0033-2658

IS - 7

ER -